Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX1 | Q9Y5S8 | 12/20 | 0.51 |
| ▸ | MEN1 | O00255 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | GAA | P10253 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | SNCA | P37840 | 3/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.51 |
| ▸ | CYBB | P04839 | 2/20 | 0.51 |
| ▸ | NOX3 | Q9HBY0 | 2/20 | 0.51 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 3/20 | 0.50 |
| ▸ | HTR2C | P28335 | 3/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | BCHE | P06276 | 2/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11770566 | 0.91 | SNCA (0.51) | NOX1MEN1KMT2AGAAMAPT | |
| SCHEMBL8941201 | 0.83 | NOX1 (0.55) | NOX1MEN1KMT2AGAAMAPT | |
| SCHEMBL11744639 | 0.80 | NOX1 (0.55) | NOX1MEN1KMT2AGAAMAPT | |
| SCHEMBL9185969 | 0.80 | NOX1 (0.55) | NOX1MEN1KMT2AGAAMAPT | |
| SCHEMBL9186453 | 0.80 | NOX1 (0.55) | NOX1MEN1KMT2AGAAMAPT | |
| SCHEMBL9185974 | 0.79 | NOX1 (0.54) | NOX1MEN1KMT2AGAAMAPT | |
| Phenothiazine SCHEMBL19350276 | 0.75 | NOX1 (0.74) | NOX1MEN1KMT2AGAAMAPT | |
| Phenothiazine SCHEMBL27531802 | 0.75 | NOX1 (0.81) | NOX1MEN1KMT2AGAAMAPT | |
| SCHEMBL11113272 | 0.75 | MAPT (0.48) | MEN1KMT2AGAAMAPTHTR2C | |
| SCHEMBL11770232 | 0.74 | SNCA (0.55) | NOX1MEN1KMT2AGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106568857-A | Method for measuring pipotiazine palmitate related substances | 岳阳新华达制药有限公司 | 2017-04-19 | — | — | CN | disclosed |
| US-20120035161-A1 | Novel Compositions and Methods of Treating Diseases Using the Same | CORRIDOR PHARMACEUTICALS, INC. | 2012-02-09 | — | — | US | disclosed |
| US-7981885-B2 | N-[3-substituted piperazino] alkylphenothiazines; antiproliferative agents, apoptotic agents; 5-HT receptor antagonists | IMMUNE CONTROL INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7923445-B2 | 10-{3-[4-(2-Amino)ethylpiperazinyl]propyl}2-trifluoromethylphenothiazine and analogues and derivatives; antiproliferative agents; serotonin receptor antagonists; apoptosis in activated lymphocytes, including T, B, and and mylenoma cells; asthma; antiarthritic agents; rheumatic diseeases | IMMUNE CONTROL, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| EP-2061788-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES RELATED TO ACTIVATED LYMPHOCYTES | Immune Control, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080132697-A1 | Novel compositions for treatment of diseases related to activated lymphocytes | IMMUNE CONTROL, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080125415-A1 | Novel methods for treatment of diseases related to activated lymphocytes | IMMUNE CONTROL, INC. (US) | 2008-05-29 | — | — | US | disclosed |
| WO-2008027521-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES RELATED TO ACTIVATED LYMPHOCYTES | IMMUNE CONTROL, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| EP-0213956-B1 | PYRROLIZIDINE PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS AND THEIR PREPARATION | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1990-04-04 | — | — | EP | disclosed |
| US-4734411-A | ANTIULCER | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1988-03-29 | — | — | US | disclosed |
| EP-0213956-A1 | Pyrrolizidine pharmaceutical compounds and compositions and their preparation | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1987-03-11 | — | — | EP | disclosed |
| US-4482711-A | Process for the preparation of N,N-dimethyl-10-[1-aza-[2,2,2]-bicyclo-3-octyl]-10H-2-phenothiazine sulphonamide | PHARMINDUSTRIE (FR) | 1984-11-13 | — | — | US | disclosed |
| US-4021552-A | TRANQUILIZERS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132697-A1 | Novel compositions for treatment of diseases related to activated lymphocytes | NFATC1, CD4, TPH1 | NOX1 3237/4885MEN1 4361/4885KMT2A 3733/4885 |
| US-20120035161-A1 | Novel Compositions and Methods of Treating Diseases Using the Same | NFATC1, BAX, BCL2 | NOX1 612/4885MEN1 3912/4885KMT2A 2771/4885 |
| US-20080125415-A1 | Novel methods for treatment of diseases related to activated lymphocytes | HTR5A, TPH1, TPH2 | NOX1 3003/4885MEN1 4222/4885KMT2A 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.